U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...
U.S. investment bank Goldman Sachs (GS) has published a list of stocks that it feels can help investors weather the current ...
Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ. Buy Gilead Sciences (GILD ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
14h
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
News-Medical.Net on MSN19h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Queerty on MSN8h
A once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback